Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
出版年份 2018 全文链接
标题
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
作者
关键词
-
出版物
Scientific Reports
Volume 8, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-07-10
DOI
10.1038/s41598-018-28449-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
- (2017) María Molina Vega et al. Expert Opinion on Drug Metabolism & Toxicology
- Exenatide: pharmacokinetics, clinical use, and future directions
- (2017) Filip K. Knop et al. EXPERT OPINION ON PHARMACOTHERAPY
- Epidemiology of Parkinson’s disease
- (2017) Ole-Bjørn Tysnes et al. JOURNAL OF NEURAL TRANSMISSION
- Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain
- (2017) Kymry T. Jones et al. JOURNAL OF NEUROCHEMISTRY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Projection of the prevalence of Parkinson's disease in the coming decades: Revisited
- (2017) Alexander Rossi et al. MOVEMENT DISORDERS
- Parkinson disease: Exenatide – a drug for diabetes and Parkinson disease?
- (2017) Joseph Jankovic Nature Reviews Neurology
- A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
- (2017) Jaishree Jalewa et al. NEUROPHARMACOLOGY
- Is Exenatide a Treatment for Parkinson’s Disease?
- (2017) Dilan Athauda et al. Journal of Parkinsons Disease
- Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
- (2017) Hamish Courtney et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease
- (2016) Henrik H Hansen et al. BRAIN RESEARCH
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program
- (2016) Hui Peng et al. Current Diabetes Reports
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
- (2016) Dilan Athauda et al. DRUG DISCOVERY TODAY
- PI3K/AKT signaling mediated by G protein-coupled receptors is involved in neurodegenerative Parkinson's disease (Review)
- (2016) Noriko Nakano et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
- (2016) Juhyun Song et al. Frontiers in Aging Neuroscience
- Is Axonal Degeneration a Key Early Event in Parkinson’s Disease?
- (2016) Zuzanna Kurowska et al. Journal of Parkinsons Disease
- Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice
- (2016) Giuseppe Perruolo et al. Scientific Reports
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward
- (2015) Melissa A. Stouffer et al. Nature Communications
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic
- (2014) Thomas Foltynie et al. Alzheimers & Dementia
- Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study
- (2014) Namyi Gu et al. CLINICAL THERAPEUTICS
- Role of ERK signaling in activity-dependent modifications of histone proteins
- (2014) Alessandro Ciccarelli et al. NEUROPHARMACOLOGY
- Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
- (2014) Fares Bassil et al. PROGRESS IN NEUROBIOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease
- (2013) Simon R.W. Stott et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- The current and projected economic burden of Parkinson's disease in the United States
- (2013) Stacey L. Kowal et al. MOVEMENT DISORDERS
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- (2012) Isidro Salcedo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
- (2012) Amjad Abuirmeileh et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
- (2011) Lloyd A. Greene et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- Insulin resistance impairs nigrostriatal dopamine function
- (2011) J.K. Morris et al. EXPERIMENTAL NEUROLOGY
- Animal models of Parkinson's disease
- (2011) Vernice Jackson-Lewis et al. PARKINSONISM & RELATED DISORDERS
- Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet
- (2010) Jill K. Morris et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: Time course of protection and neurorestoration
- (2010) Ann D. Cohen et al. BRAIN RESEARCH
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease
- (2008) J. A. Driver et al. DIABETES CARE
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started